NCT01780519View on ClinicalTrials.gov

The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Alzheimer's Disease (AD)
Interventions
DRUG

lorazepam

single dose of 1 mg lorazepam

Trial Locations (1)

85259

Mayo Clinic, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT01780519 - The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms | Biotech Hunter | Biotech Hunter